Profilo
George Uy worked as an Executive Director of Marketing at Abraxis BioScience, Inc. He then worked as a Vice President of Sales & Marketing at Spectrum Pharmaceuticals, Inc. from 2007 to 2011.
Later, he worked as a Chief Commercial Officer & Executive VP at Sorrento Therapeutics, Inc. from 2013 to 2015.
Mr. Uy received his undergraduate degree from Cebu Institute of Medicine.
Precedenti posizioni note di George Uy
| Società | Posizione | Fine |
|---|---|---|
| SORRENTO THERAPEUTICS, INC. | Corporate Officer/Principal | 31/07/2015 |
| SPECTRUM PHARMACEUTICALS, INC. | Vendite & Marketing | 01/06/2011 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Vendite & Marketing | - |
Formazione di George Uy
| Cebu Institute of Medicine | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
- Borsa valori
- Insiders
- George Uy
